OLARATUMAB for Liposarcoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 10 adverse event reports in the FDA FAERS database where OLARATUMAB was used for Liposarcoma.
Most Reported Side Effects for OLARATUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 124 | 22.0% | 32 | 29 |
| Neutropenia | 66 | 11.7% | 2 | 11 |
| Infusion related reaction | 64 | 11.3% | 2 | 25 |
| Febrile neutropenia | 57 | 10.1% | 6 | 36 |
| Drug ineffective | 49 | 8.7% | 10 | 12 |
| Death | 44 | 7.8% | 44 | 3 |
| Malignant neoplasm progression | 43 | 7.6% | 10 | 8 |
| Product use in unapproved indication | 40 | 7.1% | 7 | 14 |
| Disease progression | 33 | 5.8% | 10 | 5 |
| Anaphylactic reaction | 29 | 5.1% | 0 | 13 |
| Dyspnoea | 27 | 4.8% | 4 | 12 |
| Diarrhoea | 21 | 3.7% | 2 | 11 |
| Fatigue | 20 | 3.5% | 1 | 2 |
| Nausea | 19 | 3.4% | 1 | 5 |
| Neoplasm recurrence | 19 | 3.4% | 1 | 0 |
Other Indications for OLARATUMAB
Soft tissue sarcoma (156)
Product used for unknown indication (146)
Leiomyosarcoma (33)
Undifferentiated sarcoma (27)
Sarcoma (26)
Sarcoma metastatic (21)
Uterine leiomyosarcoma (14)
Leiomyosarcoma metastatic (13)
Endometrial stromal sarcoma (12)
Non-small cell lung cancer (11)
Other Drugs Used for Liposarcoma
PALBOCICLIB (90)
DOXORUBICIN (65)
TRABECTEDIN (59)
ERIBULIN (49)
IFOSFAMIDE (44)
PAZOPANIB (43)
NIVOLUMAB (17)
RIBOCICLIB (13)
DOCETAXEL (12)
GEMCITABINE (12)